MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Minerva Neurosciences Long Term Debt Current 2011-2026 | NERV
Annual Long Term Debt Current Minerva Neurosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 111 K | 173 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 173 K | 111 K | 142 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Exelixis
EXEL
|
27.9 M | $ 48.7 | - | $ 13.2 B | USA |
 |
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
2.13 M | $ 2.55 | - | $ 71.1 M | USA |
 |
Genmab A/S
GMAB
|
26 M | $ 27.89 | - | $ 17.2 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
117 M | $ 8.41 | - | $ 6.83 B |  Spain |
 |
InflaRx N.V.
IFRX
|
257 K | $ 2.5 | - | $ 168 M | Germany |
 |
Ionis Pharmaceuticals
IONS
|
9.51 M | $ 76.85 | - | $ 12.3 B | USA |
 |
BioNTech SE
BNTX
|
45 M | $ 95.26 | - | $ 27.2 B | Germany |
 |
Kymera Therapeutics
KYMR
|
11.9 M | $ 86.26 | - | $ 7.29 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
1.27 M | $ 232.55 | - | $ 4.25 B | USA |
 |
INmune Bio
INMB
|
623 K | $ 1.52 | - | $ 37.6 M | USA |
 |
Liquidia Corporation
LQDA
|
900 K | $ 42.14 | - | $ 3.63 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
9.96 M | $ 21.48 | - | $ 3.56 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
2.14 M | $ 110.08 | - | $ 5.53 B | USA |
 |
MannKind Corporation
MNKD
|
2.11 M | $ 3.56 | - | $ 1.09 B | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 3.35 | - | $ 5.51 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | Canada |
 |
Matinas BioPharma Holdings
MTNB
|
694 K | $ 0.68 | - | $ 3.72 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
3.25 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 24.17 | - | $ 3.08 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |